Baird Maintains Outperform on Castle Biosciences, Raises Price Target to $34
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Catherine Ramsey maintains an Outperform rating on Castle Biosciences (NASDAQ:CSTL) and raises the price target from $33 to $34.
May 03, 2024 | 10:56 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Baird analyst Catherine Ramsey maintains an Outperform rating on Castle Biosciences and raises the price target from $33 to $34.
The increase in price target by Baird reflects a positive outlook on Castle Biosciences, likely due to strong company fundamentals or growth prospects. This endorsement from a reputable analyst could lead to increased investor confidence and a potential short-term uplift in CSTL's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100